Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
暂无分享,去创建一个
Sunil Kumar Singh | A. Rana | D. Principe | Navin Viswakarma | Ajay Rana | Basabi Rana | Gautam Sondarva | Sandeep Kumar | Sandeep Kumar | Daniel R Principe | N. Viswakarma | B. Rana | Gautam Sondarva
[1] Zhe Shi,et al. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC , 2016, Oncology letters.
[2] S. Loi,et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer , 2017, Nature Communications.
[3] C. Kramm,et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy , 2013, Cancer Immunology, Immunotherapy.
[4] A. Bardia,et al. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations , 2019, The oncologist.
[5] A. Vercelli,et al. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria , 2012, Molecular and Cellular Neuroscience.
[6] Maurizio Pellecchia,et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site , 2008, Proceedings of the National Academy of Sciences.
[7] A. Winoto,et al. ERK5 MAPK Regulates Embryonic Angiogenesis and Acts as a Hypoxia-sensitive Repressor of Vascular Endothelial Growth Factor Expression* , 2002, The Journal of Biological Chemistry.
[8] J. Pouysségur,et al. The role of erk1 and erk2 in multiple stages of T cell development. , 2005, Immunity.
[9] J. Hunt,et al. Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance , 2019, PloS one.
[10] D. Morrison,et al. Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. , 2016, Molecular cell.
[11] Ken Jacobson,et al. MAP kinases and cell migration , 2004, Journal of Cell Science.
[12] T. Tan,et al. Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[13] E. Wagner,et al. Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT). , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] Dean M. Messing,et al. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. , 2011, Bioorganic & medicinal chemistry letters.
[15] Jianhua Yang,et al. MEKK2 Is Required for T-cell Receptor Signals in JNK Activation and Interleukin-2 Gene Expression* , 2001, The Journal of Biological Chemistry.
[16] R. Nahta,et al. P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. , 2013, Current medicinal chemistry.
[17] A. Gilmartin,et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). , 2011, ACS medicinal chemistry letters.
[18] Halli E. Miller,et al. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression , 2019, Cancer Immunology Research.
[19] David W. Anderson,et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] C. Marshall,et al. Activation of the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway by Conventional, Novel, and Atypical Protein Kinase C Isotypes , 1998, Molecular and Cellular Biology.
[21] F. Farhat,et al. Correlation of P38 Mitogen-Activated Protein Kinase Expression to Clinical Stage in Nasopharyngeal Carcinoma , 2018, Open access Macedonian journal of medical sciences.
[22] C. Garbe,et al. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. , 2017, European journal of cancer.
[23] T. Kinoshita,et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. , 2005, Biochemical and biophysical research communications.
[24] R. Seger,et al. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. , 2011, Biochimica et biophysica acta.
[25] S. Alzabin,et al. Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation , 2009, The Journal of Immunology.
[26] S. Papa,et al. JNK signalling in cancer: in need of new, smarter therapeutic targets , 2014, British journal of pharmacology.
[27] Teiji Wada,et al. Mitogen-activated protein kinases in apoptosis regulation , 2004, Oncogene.
[28] R. Davis,et al. Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.
[29] T. Tan,et al. GLK/MAP4K3 overexpression associates with recurrence risk for non-small cell lung cancer , 2016, Oncotarget.
[30] C. Teuscher,et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. , 2011, Blood.
[31] M. Okada,et al. The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo , 2016, Oncotarget.
[32] P. Stork,et al. Regulation of the Small GTPase Rap1 and Extracellular Signal-Regulated Kinases by the Costimulatory Molecule CTLA-4 , 2005, Molecular and Cellular Biology.
[33] P. Wee,et al. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.
[34] Lixin Wei,et al. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells , 2008, BMC Cancer.
[35] E. Gelfand,et al. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation. , 2009, The Journal of allergy and clinical immunology.
[36] G. Landreth,et al. ERK1-Deficient Mice Show Normal T Cell Effector Function and Are Highly Susceptible to Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.
[37] Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. , 2009, Bioorganic & medicinal chemistry letters.
[38] Douglas B. Evans,et al. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. , 2009, Cancer research.
[39] George Nicolae Daniel Ion,et al. In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile , 2020, Molecules.
[40] J. Hou,et al. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression , 2014, Nature Communications.
[41] H. Schaeffer,et al. Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers , 1999, Molecular and Cellular Biology.
[42] H. Shih,et al. Nuclear Factor of Activated T Cells c Is a Target of p38 Mitogen-Activated Protein Kinase in T Cells , 2003, Molecular and Cellular Biology.
[43] R. Atkins,et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. , 2007, Journal of the American Society of Nephrology : JASN.
[44] R. Flavell,et al. c-Jun NH2-Terminal Kinase (JNK)1 and JNK2 Have Distinct Roles in CD8+ T Cell Activation , 2002, The Journal of experimental medicine.
[45] S. Hedrick,et al. The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival1 , 2008, The Journal of Immunology.
[46] K. Ohkusu-Tsukada,et al. Targeted inhibition of IL‐10‐secreting CD25− Treg via p38 MAPK suppression in cancer immunotherapy , 2010, European journal of immunology.
[47] Philippe P Roux,et al. Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.
[48] Huai Gao,et al. The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor. , 2011, ACS medicinal chemistry letters.
[49] J. Siekierka,et al. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. , 1999, Journal of immunology.
[50] T. Tan,et al. MAP4K3/GLK in autoimmune disease, cancer and aging , 2019, Journal of Biomedical Science.
[51] M. C. Hu,et al. Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase. , 1999, Oncogene.
[52] Huitu Liu,et al. MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.
[53] Ding Ma,et al. The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer , 2016, Cancer biology & therapy.
[54] Jenny Bain,et al. BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo* , 2005, Journal of Biological Chemistry.
[55] The mechanism by which MEK/ERK regulates JNK and p38 activity in polyamine depleted IEC-6 cells during apoptosis , 2014, Apoptosis.
[56] M. Belvin,et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.
[57] V. Lafont,et al. Evidence for a p21 ras /Raf-1/MEK-1/ERK-2-independent Pathway in Stimulation of IL-2 Gene Transcription in Human Primary T Lymphocytes* , 1999, The Journal of Biological Chemistry.
[58] Michael Karin,et al. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.
[59] Suzanne F. Jones,et al. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors , 2019, Investigational New Drugs.
[60] T. Tan,et al. AhR–ROR-γt complex is a therapeutic target for MAP4K3/GLKhighIL-17Ahigh subpopulation of systemic lupus erythematosus , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[61] W. R. Bishop,et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. , 2018, JCI insight.
[62] Jan Richter,et al. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs? , 2019, Cell medicine.
[63] A. Cuenda,et al. p38 MAP-kinases pathway regulation, function and role in human diseases. , 2007, Biochimica et biophysica acta.
[64] E. D. de Vries,et al. MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells , 2019, The Journal of pathology.
[65] M. Prados,et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.
[66] Xiaolin Nan,et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway , 2015, Proceedings of the National Academy of Sciences.
[67] Liuxing Wang,et al. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma-not otherwise specified , 2017, Molecular medicine reports.
[68] K. Gadkar,et al. Clinical responses to ERK inhibitor (GDC-0994) treatment combinations predicted using a Quantitative Systems Pharmacology model of MAPK signaling in BRAF(V600E)-mutant colorectal cancer , 2016 .
[69] V. Keshamouni,et al. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion , 2001, Oncogene.
[70] T. Tan,et al. GLK-IKKβ signaling induces dimerization and translocation of the AhR-RORγt complex in IL-17A induction and autoimmune disease , 2018, Science Advances.
[71] S. Mehrotra,et al. Rescuing Melanoma Epitope-Specific Cytolytic T Lymphocytes from Activation-Induced Cell Death, by SP600125, an Inhibitor of JNK: Implications in Cancer Immunotherapy1 , 2004, The Journal of Immunology.
[72] T. Tan,et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses , 2007, Nature Immunology.
[73] J. Gutkind,et al. Novel insights into G protein and G protein-coupled receptor signaling in cancer. , 2014, Current opinion in cell biology.
[74] D. Bluemke,et al. Physical activity and right ventricular structure and function. The MESA-Right Ventricle Study. , 2011, American journal of respiratory and critical care medicine.
[75] J. Cicenas,et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer , 2017, Cancers.
[76] A. Baker,et al. The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines , 2015, Journal of Experimental & Clinical Cancer Research.
[77] C. Cooke,et al. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma , 2006, Oncogene.
[78] M. C. Hu,et al. Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IκB kinases (IKK-α/β) and IKK-β is a developmentally regulated protein kinase , 1999, Oncogene.
[79] L. Cope,et al. Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival , 2014, Clinical Cancer Research.
[80] M. C. Hu,et al. Murine p38-δ Mitogen-activated Protein Kinase, a Developmentally Regulated Protein Kinase That Is Activated by Stress and Proinflammatory Cytokines* , 1999, The Journal of Biological Chemistry.
[81] Taebo Sim,et al. Discovery of potent and selective covalent inhibitors of JNK. , 2012, Chemistry & biology.
[82] A. Schulze,et al. NFATc1 controls the cytotoxicity of CD8+ T cells , 2017, Nature Communications.
[83] Manish R. Patel,et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.
[84] R. Campbell,et al. Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity , 2011, Molecular Cancer Therapeutics.
[85] Nancy Y. Ip,et al. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.
[86] R. Flavell,et al. JNK is required for effector T-cell function but not for T-cell activation , 2000, Nature.
[87] H. Schulze-Koops,et al. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells , 2006, Arthritis research & therapy.
[88] G. Rassidakis,et al. AP-1 Transcription Factors as Regulators of Immune Responses in Cancer , 2019, Cancers.
[89] P. Lapinski,et al. Regulation of Ras signal transduction during T cell development and activation. , 2012, American journal of clinical and experimental immunology.
[90] D. Huo,et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. , 2006, Cancer research.
[91] G. Fanger,et al. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. , 1998, Science.
[92] M. Barančík,et al. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.